FranceMed Pharma is a privately owned British company, with solid base in the UK, since established in 1981. Active in Discovery / pioneering work in FMCG, Medical Devices and OTC, mainly related to:
Discovery/R&D/ Synthesis/ Screening/ Pre-Clinical/ Clinical (Phase I, II and III), MHRA Registration, Manufacturing, Sales, Marketing and global licensing - with main strength in Discovery.
Its unique Ethical/OTC product range, developed over the last three decades, is available in the UK and Export markets.
In the UK, its OTC range is available from doctors via the NHS prescription re-imbursement scheme as well as pharmacies and major retailers.
FranceMed Pharma is the sole global manufacturer of its range of products.
FranceMed Pharma’s micro-fine topical sprays are patented, Discovery/World's First and employ a Disruptive Unique Technology.
Commercially classified as Greenfield products with No Competition, No Me-Too's and No Generics. Clinically proven to work instantly and safely and to achieve long lasting effect, setting a new Gold Standard for treating various skin conditions.
Its Discovery “Instant T-CNS Signalling System”™ disruptive delivery technology allows a number of stimuli e.g. chemical, thermal and mechanical to be applied topically and simultaneously on the affected areas achieving greater efficacy than when applying each stimulus in turn. The efficacy is not just symptomatic as repetitive use is clinically proven to reduce or treat the underlying condition with no side effects.